MARKET

CYAD

CYAD

Celyad
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.98
-0.02
-0.18%
Closed 16:00 11/20 EST
OPEN
12.54
PREV CLOSE
11.00
HIGH
12.58
LOW
10.98
VOLUME
143.40K
TURNOVER
--
52 WEEK HIGH
28.35
52 WEEK LOW
8.10
MARKET CAP
153.09M
P/E (TTM)
-3.3450
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CYAD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CYAD News

  • I, BCRX, AGRX and THMO among midday movers
  • Seeking Alpha - Article.1d ago
  • Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights
  • Business Wire.2d ago
  • Celyad SA (CYAD) Moves to Buy: Rationale Behind the Upgrade
  • Zacks.11/13 14:00
  • Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
  • GlobeNewswire.11/11 06:00

More

Industry

Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About CYAD

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
More

Webull offers Celyad SA (CYAD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.